logo

For the Inventor, By the Inventor

Boxborough, MA, United States of America

Rachel B Kent

This inventor holds 15 USPTO granted patents and 6 published patent applications. Top assignees: Dyax Corporation, Protein Engineering Corporation, Acceleron Pharma Inc.. Active years: 1992-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rachel B Kent. Retrieved from https://idiyas.com/inventor/rachel-b-kent

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 

% Patents Active = 66.7

Average Co-Inventor Count = 5.7

ph-index = 13

Forward Citations = 5,250(Granted Patents)


Location History:

  • Wilmington, MA (US) (1992)
  • Boxborough, MA (US) (1993 - 2017)

Company Filing History:

goldMedal9 out of 174 
 
Dyax Corporation
 patents
silverMedal5 out of 5 
 
Protein Engineering Corporation
 patents
bronzeMedal1 out of 172 
 
Acceleron Pharma Inc.
 patents
4. 1 out of 834,453 
Other
 patents
where one patent can have more than one assignee

Years Active: 1992-2017

Loading Chart...
15 patents (USPTO):Explore Patents
1. 9624301 - Polynucleotides encoding an actriib antibody (2017-04-18),
2. 8765385 - Method of detection of neutralizing anti-actriib antibodies (2014-07-01),
3. 7893007 - Directed evolution of novel binding proteins (2011-02-22),
4. 7413537 - Directed evolution of disulfide-bonded micro-proteins (2008-08-19),
5. 7208293 - Directed evolution of novel binding proteins (2007-04-24),
6. 7118879 - Method of recovering a nucleic acid encoding a proteinaceous binding domain which binds a target material (2006-10-10),
7. 7078383 - ITI-D1 Kunitz domain mutants as HNE inhibitors (2006-07-18),
8. 6979538 - Directed evolution of novel binding proteins (2005-12-27),
9. 5837500 - Directed evolution of novel binding proteins (1998-11-17),
10. 5663143 - Engineered human-derived kunitz domains that inhibit human neutrophil (1997-09-02),
11. 5571698 - Directed evolution of novel binding proteins (1996-11-05),
12. 5403484 - Viruses expressing chimeric binding proteins (1995-04-04),
13. 5223409 - Directed evolution of novel binding proteins (1993-06-29),
14. 5198346 - Generation and selection of novel DNA-binding proteins and polypeptides (1993-03-30),
15. 5096815 - Generation and selection of novel DNA-binding proteins and polypeptides (1992-03-17),

Title: Rachel B Kent: Innovator in Antibody Research

Introduction

Rachel B Kent is a prominent inventor based in Boxborough, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 15 patents to her name, Rachel has established herself as a leading figure in her area of expertise.

Latest Patents

Among her latest patents is a groundbreaking invention titled "Polynucleotides encoding an ActRIIB antibody." This patent discloses neutralizing antibodies and portions thereof that bind to ActRIIB, along with various applications for these antibodies. Another notable patent is the "Method of detection of neutralizing anti-ActRIIB antibodies," which also focuses on neutralizing antibodies that interact with ActRIIB and their uses.

Career Highlights

Throughout her career, Rachel has worked with several esteemed organizations, including Dyax Corporation and Protein Engineering Corporation. Her work in these companies has allowed her to advance her research and contribute to the development of innovative solutions in the field of antibody technology.

Collaborations

Rachel has collaborated with notable professionals in her field, including Robert Charles Ladner and Arthur Charles Ley. These collaborations have further enriched her research and expanded the impact of her inventions.

Conclusion

Rachel B Kent is a distinguished inventor whose work in antibody research has led to significant advancements in biotechnology. Her numerous patents and collaborations highlight her dedication to innovation and her contributions to the scientific community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…